By reducing pro-inflammatory cytokines and promoting an anti-inflammatory environment, GLP-1 and its analogs offer promising therapeutic options for managing chronic inflammatory conditions in metabolic and neurodegenerative diseases. This evidence concerns the gene GLP1R and neurodegenerative disease.